Impact of concomitant chemotherapy on HIV resistance to cART and reservoir size

同步化疗对 HIV 对 cART 耐药性和储库大小的影响

基本信息

  • 批准号:
    10544715
  • 负责人:
  • 金额:
    $ 33.73万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-01-08 至 2024-12-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Patients with HIV infection are living longer thanks to combination antiretroviral therapy (cART), but they often necessitate treatment for comorbidities. Our long-term goal is to improve the lives of HIV-infected patients with comorbid cancer, a main cause of mortality in the cART era. HIV-infected patients with comorbid cancer have a higher risk of dying as a result of their cancer than non-HIV-infected patients. Several studies have demonstrated an association between ineffective (non-suppressive) cART and poor response to cancer chemotherapy (CHEMO) and mortality. Identification of the factors controlling the effectiveness of cART in the context of CHEMO could reduce cancer deaths in HIV-infected patients. We reasoned that CHEMO could modulate the antiviral activity of cART, based on the observation that inhibition of cellular thymidylate synthase (TS), a main target of CHEMO, alters intracellular concentrations of various nucleotides. Our goal is to evaluate the effects of TSi on the antiviral activity of cART. Our hypothesis is that TS inhibitors (TSi) can have inhibitory and enhancing effects on cART, impacting development of HIV resistance and the HIV reservoir in vivo. In Preliminary Studies, gemcitabine (GCB) enhanced the anti-HIV activities of NRTIs TFV, ABC and FTC in primary cells. In contrast, pemetrexed (PTX) inhibited FTC and 3TC activities. Mechanistic studies showed that PTX lowered the concentrations of FTCtp relative to its competing endogenous nucleotide (dCTP), which is a determinant of FTC efficacy in primary cells. Consistent with these data, the TFV/FTC/dolutegravir combination suppressed HIV in the absence, but not in the presence, of PTX. These data suggested that HIV-infected patients treated with certain cART/TSi combinations could actually have only 2, rather than 3, active ARTs, decreasing the overall potency of cART, increasing the risk of drug resistance and expanding HIV reservoirs. Preliminary Studies in humanized mice demonstrated that GCB enhances TFV inhibition of plasma HIV RNA by up to 6 log10 units, whereas PTX abrogated FTC activity. These data are the first evidence that TSi-based CHEMO can have opposing effects on cART efficacy in vivo, impacting control of HIV and thereby development of viral resistance and size of the reservoir. This proposal will evaluate the effects of PTX, GCB and other approved TSi on cART efficacy. There are three Specific Aims. Specific Aim 1: To evaluate and characterize the effects of TS inhibitors (TSi) on the anti-HIV activities of NRTIs in primary CD4+ T cells in vitro and in humanized mice. Specific Aim 2: To evaluate the impact of cART/TSi combinations on the resting CD4 T cell HIV reservoir. Specific Aim 3: To evaluate durability (lack of HIV resistance emergence) and toxicity of cART/TSi combinations during long-term treatment of HIV infection. Currently there are no treatment guidelines for the use of cART and CHEMO in HIV-infected patients with cancer, but this proposal could help to delineate guidelines and decrease cancer deaths in patients with HIV.
项目摘要 由于联合抗逆转录病毒疗法(cART),艾滋病毒感染患者的寿命更长,但他们往往 需要治疗合并症。我们的长期目标是改善艾滋病毒感染者的生活 合并癌症,这是cART时代死亡的主要原因。HIV感染者合并症 与未感染艾滋病毒的患者相比,癌症患者因癌症而死亡的风险更高。几 研究表明,无效(非抑制性)cART与对 癌症化疗(CHEMO)和死亡率。确定控制有效性的因素, 在化疗的背景下,cART可以减少艾滋病毒感染患者的癌症死亡。我们推断 CHEMO可以调节cART的抗病毒活性,这是基于观察到抑制细胞增殖, 胸苷酸合成酶(TS)是CHEMO的主要靶点,其改变细胞内各种 个核苷酸我们的目标是评估TSi对cART抗病毒活性的影响。我们的假设是 TS抑制剂(TSi)可对cART产生抑制和增强作用,影响HIV的发展 耐药性和体内HIV储存库。在初步研究中,吉西他滨(GCB)增强了抗HIV NRTI TFV、ABC和FTC在原代细胞中的活性。相比之下,培美曲塞(PTX)可抑制FTC, 3 TC活动机制研究表明,PTX降低了FTCtp的浓度, 竞争性内源核苷酸(dCTP),其是原代细胞中FTC功效的决定因素。一致 根据这些数据,TFV/FTC/度鲁特韦组合在不存在的情况下抑制HIV,但在不存在的情况下不抑制HIV。 存在,PTX。这些数据表明,接受某些cART/TSi治疗的HIV感染患者 联合用药实际上可能只有2种而不是3种活性ART,降低了cART的总体效力, 增加了耐药性的风险,扩大了艾滋病毒的储存库。人源化小鼠的初步研究 证明GCB可使TFV对血浆HIV RNA的抑制作用增强6 log 10单位,而PTX 取消FTC活动。这些数据是第一个证据表明,基于TSi的CHEMO可以有反对 影响体内cART疗效,影响HIV控制,从而产生病毒耐药性 和水库的大小。本提案将评估PTX、GCB和其他获批TSi对 cART疗效。有三个具体目标。具体目标1:评价和表征TS的作用 抑制剂(TSi)对NRTI在体外和人源化小鼠中的原代CD 4 + T细胞中的抗HIV活性的影响。 具体目的2:评价cART/TSi组合对静息CD 4 T细胞HIV储库的影响。 具体目标3:评价cART/TSi的持久性(缺乏HIV耐药性出现)和毒性 在长期治疗HIV感染的过程中。目前还没有治疗指南, 在HIV感染的癌症患者中使用cART和CHEMO,但这一建议可能有助于描述 指导方针并减少艾滋病毒患者的癌症死亡。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Use of Humanized Mouse Models for Studying HIV-1 Infection, Pathogenesis and Persistence.
使用人源化小鼠模型研究 HIV-1 感染、发病机制和持久性。
  • DOI:
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Weichseldorfer,Matthew;Heredia,Alonso;Reitz,Marvin;Bryant,JosephL;Latinovic,OlgaS
  • 通讯作者:
    Latinovic,OlgaS
Humanized mouse models for preclinical evaluation of HIV cure strategies.
  • DOI:
    10.24875/aidsrev.22000013
  • 发表时间:
    2022-10-25
  • 期刊:
  • 影响因子:
    2.2
  • 作者:
    Fraker, Sally;Atkinson, Benjamin;Heredia, Alonso
  • 通讯作者:
    Heredia, Alonso
Human Hematopoietic Stem Cell (HSC)-Engrafted NSG Mice for HIV Latency Research.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Alonso Heredia其他文献

Alonso Heredia的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Alonso Heredia', 18)}}的其他基金

Image-guided intra-arterial administration of antibody-releasing glial progenitors to control the HIV CNS reservoir.
图像引导动脉内注射抗体释放神经胶质祖细胞来控制 HIV 中枢神经系统储库。
  • 批准号:
    10512770
  • 财政年份:
    2022
  • 资助金额:
    $ 33.73万
  • 项目类别:
Image-guided intra-arterial administration of antibody-releasing glial progenitors to control the HIV CNS reservoir.
图像引导动脉内注射抗体释放神经胶质祖细胞来控制 HIV 中枢神经系统储库。
  • 批准号:
    10684314
  • 财政年份:
    2022
  • 资助金额:
    $ 33.73万
  • 项目类别:
Impact of concomitant chemotherapy on HIV resistance to cART and reservoir size
同步化疗对 HIV 对 cART 耐药性和储库大小的影响
  • 批准号:
    10321231
  • 财政年份:
    2019
  • 资助金额:
    $ 33.73万
  • 项目类别:
Long-Term Inhibition of HIV transcription by targeting cellular CDK9 in vivo.
通过体内靶向细胞 CDK9 长期抑制 HIV 转录。
  • 批准号:
    8788234
  • 财政年份:
    2014
  • 资助金额:
    $ 33.73万
  • 项目类别:
Long-Term Inhibition of HIV transcription by targeting cellular CDK9 in vivo.
通过体内靶向细胞 CDK9 长期抑制 HIV 转录。
  • 批准号:
    8847280
  • 财政年份:
    2014
  • 资助金额:
    $ 33.73万
  • 项目类别:
Control of HIV drug resistance in older patients
老年患者艾滋病毒耐药性的控制
  • 批准号:
    7753133
  • 财政年份:
    2009
  • 资助金额:
    $ 33.73万
  • 项目类别:
Control of HIV drug resistance in older patients
老年患者艾滋病毒耐药性的控制
  • 批准号:
    7897760
  • 财政年份:
    2009
  • 资助金额:
    $ 33.73万
  • 项目类别:

相似海外基金

Establishment of a new biological assay using Hydra nematocyst deployment
利用水螅刺丝囊部署建立新的生物测定方法
  • 批准号:
    520728-2017
  • 财政年份:
    2017
  • 资助金额:
    $ 33.73万
  • 项目类别:
    University Undergraduate Student Research Awards
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
  • 批准号:
    10368760
  • 财政年份:
    2017
  • 资助金额:
    $ 33.73万
  • 项目类别:
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
  • 批准号:
    10669539
  • 财政年份:
    2017
  • 资助金额:
    $ 33.73万
  • 项目类别:
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
  • 批准号:
    9570142
  • 财政年份:
    2017
  • 资助金额:
    $ 33.73万
  • 项目类别:
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
  • 批准号:
    9915803
  • 财政年份:
    2017
  • 资助金额:
    $ 33.73万
  • 项目类别:
COVID-19 Supplemental work: POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER).
COVID-19 补充工作:用于确定组织特异性吸收电离辐射剂量的护理点生物测定(生物剂量计)。
  • 批准号:
    10259999
  • 财政年份:
    2017
  • 资助金额:
    $ 33.73万
  • 项目类别:
Drug discovery based on a new biological assay system using Yeast knock-out strain collection
基于使用酵母敲除菌株收集的新生物测定系统的药物发现
  • 批准号:
    21580130
  • 财政年份:
    2009
  • 资助金额:
    $ 33.73万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Machine learning for automatic gene annotation using high-throughput biological assay data
使用高通量生物测定数据进行自动基因注释的机器学习
  • 批准号:
    300985-2004
  • 财政年份:
    2005
  • 资助金额:
    $ 33.73万
  • 项目类别:
    Postdoctoral Fellowships
Machine learning for automatic gene annotation using high-throughput biological assay data
使用高通量生物测定数据进行自动基因注释的机器学习
  • 批准号:
    300985-2004
  • 财政年份:
    2004
  • 资助金额:
    $ 33.73万
  • 项目类别:
    Postdoctoral Fellowships
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了